Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Annals of the Rheumatic Diseases 73.10 (2014): S. 1880-1887.
- Keyword
-
-
Hautkrankheit
Dermatologie
- Event
-
Veröffentlichung
- (where)
-
Erlangen
- (who)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (when)
-
2014
- Creator
-
Maurer, Britta
Distler, Alfiya
Suliman, Yossra A.
Gay, Renate E.
Michel, Beat A.
Gay, Steffen
Distler, Jörg H. W.
Distler, Oliver
- URN
-
urn:nbn:de:bvb:29-opus4-78817
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Maurer, Britta
- Distler, Alfiya
- Suliman, Yossra A.
- Gay, Renate E.
- Michel, Beat A.
- Gay, Steffen
- Distler, Jörg H. W.
- Distler, Oliver
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Time of origin
- 2014
Other Objects (12)
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models
The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis
Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis
Inhibition of sumoylation prevents experimental fibrosis
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models
The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis
Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis
Inhibition of sumoylation prevents experimental fibrosis
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models
The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis
Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis